Arjo has a longstanding tradition of developing hygiene solutions, with the systematic approach to both bathing and transfer equipment going back more than 50 years.
“Symbliss is the latest example of how we innovate premium products and solutions for real-life care situations, based on clinical insights and with caregivers as well as patients and residents in mind. The launch of Symbliss marks the beginning of a series of upcoming product launches and will enable us to take a leading position within the premium bathing market space,” says Tobias Kramer, Executive Vice President of Global Marketing at Arjo.
Symbliss is a height-adjustable integrated bathing system consisting of a bathtub and a bath chair, with a comprehensive range of unique features and functions. The system is designed according to dementia-friendly principles and has received the highest rating from the Dementia Services Development Centre (DSDC) at the University of Stirling in Scotland.
“Seeing how caregivers working under time pressure face challenges in delivering safe one-to-one care, especially during a complex and time-consuming activity like bathing, we wanted to use our unique ability to address and ease the entire workflow, from bed to bath and back again,” says Magnus Karlberg, Vice President of Research and Development at Arjo.
Symbliss enables secure bathing for residents with various mobility levels – from active and semi-active to passive. The chair and bath integration provides improved access to the resident, which results in a comfortable and safe working posture for the carer.
“The unique chair tilt function is a key enabler for achieving secure resident positioning during transfer, as well as when fully immersed in water,” adds Magnus.
An independent study1 confirms that Arjo’s Symbliss bath and chair are ergonomically safe to use by a single caregiver across mobility levels. This helps to improve efficiencies in care workflows, paving the way for time and resource savings.
Symbliss is currently available in Belgium and Sweden, with launches in the US, Canada, UK and western European countries scheduled for the first quarter of 2025.
